title: Genetically engineered antibodies in gene transfer and gene therapy.
abstract: Our ability to produce and engineer human monoclonal antibodies provides a basis for the development of novel therapeutical strategies against a variety of diseases. These strategies not only include improved passive immunotherapy but also more sophisticated antibody-based gene therapies involving gene transfer approaches. Four of the major applications of antibody gene engineering in the field of gene therapy are reviewed here. These are (1) the redefinition of viral vector tropism of infection for better transduction of cells of therapeutical interest, (2) the grafting of new cell recognition activities to effector cells of the immune system to kill cancer and pathogen-infected cells, (3) the inhibition of cellular and viral functions through intracellular expression of antibody-derived molecules, and (4) the systemic delivery of therapeutic monoclonal antibodies by non-B cells in living organisms.
authors.affiliation: Institute of Molecular Genetics of Montpellier, CNRS, France.
authors.forename: M
authors.initials: M
authors.lastname: Pelegrin
authors.forename: M
authors.initials: M
authors.lastname: Marin
authors.forename: D
authors.initials: D
authors.lastname: Noël
authors.forename: M
authors.initials: M
authors.lastname: Piechaczyk
mesh_terms: D000911:Antibodies, Monoclonal / Q000235:genetics* / Q000627:therapeutic use; D018014:Gene Transfer Techniques; D005818:Genetic Engineering; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans
chemical_list: D000911:Antibodies, Monoclonal